Pioneering Regenerative Solutions
Merakris Therapeutics is at the forefront of cell-free regenerative medicine. Here, we leverage the extraordinary healing capabilities of human amniotic tissue to develop products that transform the standard of patient care.
The company’s dedicated scientific efforts have led to groundbreaking advancements in regenerative wound care medicine.
Our rigorous research and development efforts have successfully propelled MTX-001, an investigational new drug, into Phase 2 clinical trials, marking a pivotal step in bringing our advanced regenerative therapy to patients in need.
Advanced Healing with Cutting-Edge Technology
Our research seeks to answer a fundamental question – what mechanisms underpin the regenerative healing potential of amniotic fluid.
Powered by a brilliant scientific team, Merakris Therapeutics is transforming scientific insights into a new class of cell-free therapeutics for wound care and other unmet clinical needs.
Cell-Free Amniotic Fluid (MTX-001)
Amniotic Fluid (AF), vital for fetal development, has known anti-inflammatory, anti-microbial, and regenerative properties that drive clinical applications.1
The cell-free form of amniotic fluid (cfAF) is also a powerful stimulant of healing and repair. Its immunomodulatory, anti-inflammatory and pro-growth characteristics make cfAF a valuable agent in wound healing.2
Our proprietary tissue engineering technologies involve the isolation of cfAF under the highest safety standards, while optimizing the functional potency properties of amniotic fluid
By harnessing the proteins and exosome signaling molecules within amniotic fluid, we have created a first in class cell-free solution currently in Phase II clinical trials.3
This technology represents a first-in-class approach to precision wound healing by disrupting chronic tissue damage cycle with protease inhibition and anti-inflammatory effects and increasing keratinocyte migration, fibroblast proliferation and collagen deposition.4
Complete this form to download the MTX-001 overview
Scientific Publications
Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities
Comparative Analysis of Co-Cultured Amniotic Cell-Conditioned Media with Cell-Free Amniotic Fluid Reveals Differential Effects on Epithelial-Mesenchymal Transition and Myofibroblast Activation
Safety and efficacy of acellular human amniotic fluid and membrane in the treatment of non-healing wounds in a patient with chronic venous insufficiency
Adaptive Design Clinical Trial: Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers (VSU)
Our current focus is on the clinical trial of MTX-001 (an investigational drug) in the treatment of non-healing chronic venous leg ulcers/diabetic foot ulcers (VLU/DFU) as a novel subcutaneous therapy.
Our future endeavors include expanding the scope of our technologies beyond wound care in Chronic Wounds, Rare Ulcers, Dermatology, Ophthamology, Respiratory, Orthopedics and Aesthetics.
Charting the Future of Regenerative Medicine
References:
- Pierce J et al. Cell Tissue Bank. 2016;17(3):413-425
- Bowen CM, Ditmars FS, Gupta A, Reems JA, Fagg WS. Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities. Biomedicines. 2022 Nov 17;10(11):2960.
- A Two Part, Randomized Study of Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers. ClinicalTrials.gov Identifier: NCT04647240. U.S. National Library of Medicine, 2020. https://classic.clinicaltrials.gov/ct2/show/NCT04647240 (accessed 2024-03-16).
- Liu, Naiyou, et al. “Comparative Analysis of Co-Cultured Amniotic Cell-Conditioned Media with Cell-Free Amniotic Fluid Reveals Di erential E ects on Epithelial–Mesenchymal Transition and Myobroblast Activation.” Biomedicines 10.9 (2022): 2189.